Northland Starts WW International lnc (WW) at Outperform

Northland analyst Owen Rickert initiates coverage on WW International lnc (NASDAQ: WW) with a Outperform rating and a price target of $25.00.

The analyst comments "WW operates via a combination of digital and app-based subscription services, community support, clinical telehealth services, and behavioral coaching programs that provide personalized tracking, food guidance, and group workshops (offered both virtually and in-person) foster peer accountability and sustainable habit formation. We believe WW is wellpositioned to continue making progress on its turnaround plan, and the Eli Lilly (NYSE:LLY, Not Covered), and Sam’s Club partnerships, as well as the recently announced collaboration with Google Health Enterprise are strong potential growth catalysts. Why We Like WW: 1. Uniquely Placed in the Competitive Landscape 2. Well-Positioned to Execute on its Turnaround Strategy 3. Large TAM with Multi-Layered Growth Strategy 4. Compelling Long-Term Model and Valuation WW is in the midst of a major turnaround after being hit hard by the rise of GLP-1 weight loss drugs, resulting in a significant undercut to its traditional subscription-based model. WW was also carrying ~$1.6B in debt, making it difficult to pivot and invest in new growth strategies. On May 6th, 2025, WW filed a prepackaged Chapter 11 bankruptcy in the US Bankruptcy Court for the District of Delaware and 75% of secured debt holders had already signed a restructuring support agreement before the petition which, in our view, signaled a coordinated and strategic move rather than a full-on collapse. As a result, WW stock fell ~43% the day after the announcement and was delisted from NASDAQ on May 16th, 2025."

For an analyst ratings summary and ratings history on WW International lnc click here. For more ratings news on WW International lnc click here.

Shares of WW International lnc closed at $13.72 yesterday.

You May Also Be Interested In

• Freedom Broker Upgrades Nike (NKE) to Buy
• National Healthcare Properties to convert Class A shares to common stock
• Teknova and Pluristyx file FDA drug master file for PluriFreeze system